BioSpace News Archive

ShiraTronics, Inc., a private medical device company, today announced it has completed a Series A financing of $33 million.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial results on Wednesday, November 6, 2019 after the U.S. financial markets close.

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2019.

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time.

Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.

BeyondSpring Inc. announced the launch of an underwritten public offering of its ordinary shares.

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions.

TFF Pharmaceuticals has granted the underwriter a 45-day option to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

His valuable experience will contribute towards bolstering the mission of the “Fondazione Internazionale Menarini” which welcomes the winner of the Nobel prize for Medicine, Louis Ignarro.

Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry and more than 850 partners to support the SDGs.